首頁 > 市場調查報告書 > 製藥

生物製劑分子標靶治療學

市場調查報告書

商品編碼

1881251

腫瘤單株抗體合作與授權協議（2016-2025）

Cancer Monoclonal Antibody Collaboration and Licensing Deals 2016-2025

出版日期: 2025年11月01日 | 出版商:

Current Partnering | 英文 350+ Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

"腫瘤單株抗體合作與授權協議" 全面深入分析了全球領先的生物製藥公司簽署的腫瘤單株抗體協議，並提供前所未有的資訊取得管道。

這份經過全面修訂和更新的報告詳細介紹了2016年至2025年間的腫瘤單株抗體協議。

本報告深入分析了企業簽訂腫瘤單株抗體協議的原因和方式。這些協議通常包含多個組成部分，從合作研發開始，逐步推進到成果的商業化。

本報告涵蓋合作、開發、研究和授權。

本報告包含自 2016 年以來宣布的 632 項腫瘤單株抗體交易的完整清單。該報告還提供了指向實際癌症單株抗體合作交易在線記錄的鏈接，包括可用的財務條款以及交易雙方披露的條款。此外，在條件允許的情況下，記錄還包括公司及其合作夥伴向美國證券交易委員會提交的合約文件。

本報告的引言概述了癌症單株抗體交易。

第一章概述了本報告。

第二章概述了自 2016 年以來癌症單株抗體交易的趨勢。

第三章概述了自 2016 年以來主要的癌症單株抗體交易，並依交易額列出。

第四章提供了最活躍的 25 家癌症單株抗體交易撮合者的完整名單，並附有簡要概述，隨後提供了癌症單株抗體交易的完整列表以及公開的合約文件。

第五章對自 2016 年 1 月以來已完成或宣布的癌症單株抗體交易進行了全面深入的回顧，涵蓋了合約文件公開可取得的交易。

第六章對自2016年1月以來已達成或宣布的癌症單株抗體合作協議進行了全面深入的回顧。本章以癌症單株抗體技術的具體類型進行組織。

本報告還包含大量表格和圖表，展示了自2016年以來癌症單株抗體交易的趨勢和動態。

此外，我們還提供了一個全面的合約目錄，依公司名稱（A-Z）、合約類型和治療標靶進行分類。每個合約標題都透過網路連結指向線上合約記錄，並在可用的情況下指向合約文件，以便根據需要輕鬆查閱每個合約文件。

主要優勢

本報告 "癌症單株抗體研究合作與授權協議" 為讀者提供以下主要優勢：

了解自 2016 年以來的交易趨勢
瀏覽癌症單株抗體合作與授權協議
基準分析 - 確定交易市場價值
財務條款 - 預付款、里程碑付款、特許權使用費
依公司（A-Z）、協議類型和治療領域分類的合約目錄
以價值排名的主要交易
最活躍的交易撮合者
識別每筆交易的資產和條款
存取合約文件 - 深入了解交易結構
盡職調查 - 評估擬議交易條款對合作公司的適用性
節省數百小時的研究時間

範圍

本報告 "癌症單株抗體合作與授權協議" 旨在幫助讀者深入了解全球領先生物製藥公司之間癌症單株抗體相關協議的趨勢和結構。

本報告內容： "腫瘤單株抗體合作與授權協議"

生物製藥產業腫瘤單株抗體交易趨勢
製藥和生物技術公司腫瘤單株抗體合約記錄目錄
依價值排名的主要腫瘤單株抗體合約
最活躍的腫瘤單株抗體授權協議公司
"腫瘤單株抗體合作與許可協議" 提供對現有交易記錄（包括合約文件）的全面存取。

分析合約內容有助於對以下方面進行盡職調查：

合約具體授予或選擇哪些權利？
合約實際授予合作夥伴哪些權利？
授予了哪些排他性權利？
交易的付款結構是什麼？
銷售和付款如何審計？
合約期限是多久？
合約的關鍵條款是如何定義的？
智慧財產權（IPR）如何處理歸屬於誰？
誰負責商業化？
誰負責開發、供應和生產？
如何管理保密性和資訊揭露？
如何解決爭議？
合約在什麼情況下可以終止？
如果所有權發生變更，會發生什麼事？
如何約定轉讓許可和分包條款？
貴公司需要哪些標準條款？
哪些標準條款會因交易對手和交易類型而異？
貴公司必須在哪個司法管轄區內履行合約？

引言
歷年癌症單株抗體交易狀況
最活躍的癌症單株抗體交易商
依交易類型劃分的癌症單株抗體交易
依治療領域劃分的癌症單株抗體交易
依行業劃分的癌症單株抗體交易
癌症單株抗體交易條款
- 癌症單株抗體交易總額
- 癌症單株抗體交易預付款
- 癌症單株抗體交易里程碑付款
- 特許權使用費癌症單株抗體價格

第三章 - 主要癌症單株抗體交易

引言
以價值排名的頂級癌症單株抗體交易

第四章 - 最活躍的癌症單株抗體交易者

引言
最活躍的癌症單株抗體交易商
最活躍的癌症單株抗體交易商公司簡介

第五章 - 癌症單株抗體合約交易目錄

引言
癌症單株抗體合約交易目錄

第六章 - 依技術分類的癌症單株抗體交易

交易目錄
癌症交易目錄單株抗體交易（依公司、亞利桑那州分類）
交易目錄 - 依交易類型分類的癌症單株抗體交易
交易目錄 - 依治療領域分類的腫瘤單株抗體交易
交易類型定義
關於研究公司
當前合作夥伴關係
當前協議
依目前合作夥伴關係分類的近期報告標題

簡介目錄

Product Code: CP22012

Cancer Monoclonal Antibody Collaboration and Licensing Deals provides a comprehensive understanding and unprecedented access to the cancer monoclonal antibody deals entered into by the worlds leading biopharma companies.

Fully revised and updated, the report provides details of cancer monoclonal antibody deals from 2016 to 2025.

The report provides a detailed understanding and analysis of how and why companies enter cancer monoclonal antibody deals. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.

The report includes collaboration, development, research and licensing deals.

This report contains a comprehensive listing of 632 cancer monoclonal antibody deals announced since 2016 including financial terms where available including links to online deal records of actual cancer monoclonal antibody partnering deals as disclosed by the deal parties. In addition, where available, records include contract documents as submitted to the Securities Exchange Commission by companies and their partners.

The initial chapters of this report provide an orientation of cancer monoclonal antibody dealmaking.

Chapter 1 provides an introduction to the report.

Chapter 2 provides an overview of the trends in cancer monoclonal antibody dealmaking since 2016.

Chapter 3 provides an overview of the leading cancer monoclonal antibody deals since 2016. Deals are listed by headline value.

Chapter 4 provides a comprehensive listing of the top 25 most active companies in cancer monoclonal antibody dealmaking with a brief summary followed by a comprehensive listing of cancer monoclonal antibody deals, as well as contract documents available in the public domain.

Chapter 5 provides a comprehensive and detailed review of cancer monoclonal antibody deals signed and announced since Jan 2016, where a contract document is available in the public domain.

Chapter 6 provides a comprehensive and detailed review of cancer monoclonal antibody partnering deals signed and announced since Jan 2016. The chapter is organized by specific cancer monoclonal antibody technology type in focus.

The report also includes numerous table and figures that illustrate the trends and activities in cancer monoclonal antibody deal making since 2016.

In addition, a comprehensive deal directory is provided organized by company A-Z, deal type and therapeutic target. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

Key benefits

Cancer Monoclonal Antibody Collaboration and Licensing Deals provides the reader with the following key benefits:

Understand deal trends since 2016
Browse cancer monoclonal antibody collaboration and licensing deals
Benchmark analysis - identify market value of transactions
Financials terms - upfront, milestone, royalties
Directory of deals by company A-Z, deal type and therapy area
Leading deals by value
Most active dealmakers
Identify assets and deal terms for each transaction
Access contract documents - insights into deal structures
Due diligence - assess suitability of your proposed deal terms for partner companies
Save hundreds of hours of research time

Report scope

Cancer Monoclonal Antibody Collaboration and Licensing Deals is intended to provide the reader with an in-depth understanding of cancer monoclonal antibody trends and structure of deals entered into by leading biopharma companies worldwide.

Cancer Monoclonal Antibody Collaboration and Licensing Deals includes:

Trends in cancer monoclonal antibody dealmaking in the biopharma industry
Directory of cancer monoclonal antibody deal records covering pharmaceutical and biotechnology
The leading cancer monoclonal antibody deals by value
Most active cancer monoclonal antibody licensing dealmakers
Cancer Monoclonal Antibody Collaboration and Licensing Deals provides comprehensive access to available records for deals, including contract documents where available.

Analyzing contract agreements allows due diligence of:

What are the precise rights granted or optioned?
What is actually granted by the agreement to the partner company?
What exclusivity is granted?
What is the payment structure for the deal?
How are sales and payments audited?
What is the deal term?
How are the key terms of the agreement defined?
How are IPRs handled and owned?
Who is responsible for commercialization?
Who is responsible for development, supply, and manufacture?
How is confidentiality and publication managed?
How are disputes to be resolved?
Under what conditions can the deal be terminated?
What happens when there is a change of ownership?
What sublicensing and subcontracting provisions have been agreed?
Which boilerplate clauses does the company insist upon?
Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
Which jurisdiction does the company insist upon for agreement law?

Executive Summary

Chapter 1 - Introduction

Chapter 2 - Trends in cancer monoclonal antibody dealmaking

2.1. Introduction
2.2. Cancer monoclonal antibody deals over the years
2.3. Most active cancer monoclonal antibody dealmakers
2.4. Cancer monoclonal antibody deals by deal type
2.5. Cancer monoclonal antibody deals by therapy area
2.6. Cancer monoclonal antibody deals by industry sector
2.7. Deal terms for cancer monoclonal antibody deals
- 2.7.1 Cancer monoclonal antibody deals headline values
- 2.7.2 Cancer monoclonal antibody deal upfront payments
- 2.7.3 Cancer monoclonal antibody deal milestone payments
- 2.7.4 Cancer monoclonal antibody royalty rates